Oral semaglutide improved liver health, diabetes status, and lipid profile in patients with MASLD and T2D, with weight loss ...

People with type 2 diabetes who use semaglutide drugs like Ozempic and Wegovy appear to have a lower risk of Alzheimer's ...

Researchers have found that semaglutide may lower the risk of Alzheimer's disease in people with type 2 diabetes (T2D).

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

A new study suggests that semaglutide, used for type 2 diabetes and weight loss under brand names like Wegovy and Ozempic, ...

For patients with type 2 diabetes (T2D), duodenal recellularization via electroporation therapy (ReCET), which uses pulsed ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

The GLP-1 RA semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, real-world data show.

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

Add Alzheimer's disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new ...

Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...

According to a recent study, certain classes of weight loss drugs — including Ozempic — may have positive effects on the ...